IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel New York in New York City on Wednesday, September 23, 2026, beginning at 10:00 a.m. ET.

The event will feature a conversation with an OVATION 1 clinical trial participant offering a firsthand perspective on her experience in the study and in the years following the trial. Presentations will include leading experts in ovarian cancer and principal investigators involved in the Company's Phase 3 OVATION 3 clinical trial and the Phase 2 minimal residual disease (MRD) clinical trial, conducted in partnership with the Break Through Cancer Foundation.